4 news items
Why Bio-Path Stock Is Soaring
BPTH
18 Apr 24
Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Bio-Path said BP1002 may overcome and prevent some of the mechanisms
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BPTH
18 Apr 24
targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The current standard of care for patients
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
patients, including venetoclax-resistant patients, is ongoing. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
BPTH
1 Mar 24
, targeting the Bcl-2 protein responsible for driving cell survival in up to 60% of all cancers) has announced the enrollment and dosing of the first
- Prev
- 1
- Next